Literature DB >> 11286383

Carnitine palmitoyltransferase I deficiency in neonate identified by dried blood spot free carnitine and acylcarnitine profile.

K G Sim1, V Wiley, K Carpenter, B Wilcken.   

Abstract

A neonate at risk for hepatic carnitine palmitoyltransferase I (L-CPT I) deficiency was investigated from birth. The free carnitine and acylcarnitine profile in dried whole blood filter paper samples collected at ages 1 and 4 days showed a markedly elevated concentration of free carnitine (141 and 142 micromol/L, respectively), normal concentrations of acetyl- and propionylcarnitine, with the near absence of all other species. The diagnosis was confirmed by in vitro fatty acid oxidation screening assays and enzyme assay in cultured skin fibroblasts. Retrospective study of the newborn whole blood sample of the index case showed a similar profile (free carnitine 181 micromol/L). The newborn population distribution of free carnitine (n = 143,981) showed that only three samples had free carnitine > 140 micromol/L (>99.9th centile), two were from L-CPT I-deficient neonates and one from a baby with sepsis. While there are other conditions that can cause elevated concentrations of free carnitine, an isolated elevation of free carnitine only in an apparently healthy term neonate warrants further investigation to exclude L-CPT I deficiency.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11286383     DOI: 10.1023/a:1005606805951

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  30 in total

1.  Prenatal diagnosis of mitochondrial fatty acid oxidation defects.

Authors:  M A Nada; C Vianey-Saban; C R Roe; J H Ding; M Mathieu; R S Wappner; M G Bialer; J A McGlynn; G Mandon
Journal:  Prenat Diagn       Date:  1996-02       Impact factor: 3.050

Review 2.  The mitochondrial carnitine palmitoyltransferase system. From concept to molecular analysis.

Authors:  J D McGarry; N F Brown
Journal:  Eur J Biochem       Date:  1997-02-15

3.  Fine chromosome mapping of the genes for human liver and muscle carnitine palmitoyltransferase I (CPT1A and CPT1B).

Authors:  C H Britton; D W Mackey; V Esser; D W Foster; D K Burns; D P Yarnall; P Froguel; J D McGarry
Journal:  Genomics       Date:  1997-02-15       Impact factor: 5.736

4.  Normal muscle CPT1 and CPT2 activities in hepatic presentation patients with CPT1 deficiency in fibroblasts. Tissue specific isoforms of CPT1?

Authors:  I Tein; F Demaugre; J P Bonnefont; J M Saudubray
Journal:  J Neurol Sci       Date:  1989-09       Impact factor: 3.181

5.  Rapid diagnosis of homocystinuria and other hypermethioninemias from newborns' blood spots by tandem mass spectrometry.

Authors:  D H Chace; S L Hillman; D S Millington; S G Kahler; B W Adam; H L Levy
Journal:  Clin Chem       Date:  1996-03       Impact factor: 8.327

6.  Fasting hypoglycemia resulting from hepatic carnitine palmitoyl transferase deficiency.

Authors:  P F Bougnères; J M Saudubray; C Marsac; O Bernard; M Odièvre; J Girard
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

7.  Mouse white adipocytes and 3T3-L1 cells display an anomalous pattern of carnitine palmitoyltransferase (CPT) I isoform expression during differentiation. Inter-tissue and inter-species expression of CPT I and CPT II enzymes.

Authors:  N F Brown; J K Hill; V Esser; J L Kirkland; B E Corkey; D W Foster; J D McGarry
Journal:  Biochem J       Date:  1997-10-01       Impact factor: 3.857

8.  Carnitine status at birth of newborn infants of varying gestation.

Authors:  J P Shenai; P R Borum; P Mohan; S C Donlevy
Journal:  Pediatr Res       Date:  1983-07       Impact factor: 3.756

9.  Hepatic and muscular presentations of carnitine palmitoyl transferase deficiency: two distinct entities.

Authors:  F Demaugre; J P Bonnefont; G Mitchell; N Nguyen-Hoang; A Pelet; M Rimoldi; S Di Donato; J M Saudubray
Journal:  Pediatr Res       Date:  1988-09       Impact factor: 3.756

10.  Characterisation of carnitine palmitoyltransferases in patients with a carnitine palmitoyltransferase deficiency: implications for diagnosis and therapy.

Authors:  J Schaefer; S Jackson; F Taroni; P Swift; D M Turnbull
Journal:  J Neurol Neurosurg Psychiatry       Date:  1997-02       Impact factor: 10.154

View more
  6 in total

1.  Lethal neonatal presentation of carnitine palmitoyltransferase I deficiency.

Authors:  F Invernizzi; A B Burlina; A Donadio; G Giordano; F Taroni; B Garavaglia
Journal:  J Inherit Metab Dis       Date:  2001-10       Impact factor: 4.982

2.  Normal Levels of Plasma Free Carnitine and Acylcarnitines in Follow-Up Samples from a Presymptomatic Case of Carnitine Palmitoyl Transferase 1 (CPT1) Deficiency Detected Through Newborn Screening in Denmark.

Authors:  Luise Borch; Allan Meldgaard Lund; Flemming Wibrand; Ernst Christensen; Charlotte Søndergaard; Birthe Gahrn; David Michael Hougaard; Brage Storstein Andresen; Niels Gregersen; Rikke Katrine Jentoft Olsen
Journal:  JIMD Rep       Date:  2011-09-22

3.  Evaluation of newborn screening for medium chain acyl-CoA dehydrogenase deficiency in 275 000 babies.

Authors:  K Carpenter; V Wiley; K G Sim; D Heath; B Wilcken
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2001-09       Impact factor: 5.747

4.  CPT1A: the future of heart disease detection and personalized medicine?

Authors:  M Ryan Irvin; Stella Aslibekyan; Bertha Hidalgo; Donna Arnett
Journal:  Clin Lipidol       Date:  2014

5.  Reliable Diagnosis of Carnitine Palmitoyltransferase Type IA Deficiency by Analysis of Plasma Acylcarnitine Profiles.

Authors:  M Rebecca Heiner-Fokkema; Frédéric M Vaz; Ronald Maatman; Leo A J Kluijtmans; Francjan J van Spronsen; Dirk-Jan Reijngoud
Journal:  JIMD Rep       Date:  2016-06-14

Review 6.  Disorders of mitochondrial long-chain fatty acid oxidation and the carnitine shuttle.

Authors:  Suzan J G Knottnerus; Jeannette C Bleeker; Rob C I Wüst; Sacha Ferdinandusse; Lodewijk IJlst; Frits A Wijburg; Ronald J A Wanders; Gepke Visser; Riekelt H Houtkooper
Journal:  Rev Endocr Metab Disord       Date:  2018-03       Impact factor: 6.514

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.